Providing therapy with dose administration aids and existing cardiovascular medicines - Pilot

Not Applicable

Completed

• Conditions: Cardiovascular disease; Public Health - Other public health; Medication adherence; Cardiovascular - Other cardiovascular diseases

• Registration Number: ACTRN12620001239954
• Lead Sponsor: The George Institute for Global Health

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2020-11-19
• Study Completion: 2021-12-12
• Last Update Posted: 4 March 2024

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 100

Inclusion Criteria

Participant inclusion criteria:
1. Community dwelling adults aged greater than equal to 18 years old
2. Prescribed at least 5 medicines, with at least 1 cardiovascular indication which includes medications for coronary artery disease, stroke, peripheral vascular disease, hypertension, hypercholesterolaemia, diabetes, arrhythmias, heart failure and valvular heart disease. Broadly this includes Pharmaceutical Benefits Scheme Anatomical Therapeutic Chemical Classifications A10, B01, B02, C01-C10.
3. Stable medical conditions and stable medications for at least 6 months prior to enrolment
4. Ability to give informed consent

Site selection criteria:
Primary care practices using electronic health records that have the ability to generate practice-level reports of the target population and have regular data extractions performed via MedicineInsight or network processes.

Exclusion Criteria

Participant exclusion criteria:
1. Responsible primary care or other responsible physician believes it is not appropriate for the patient to participate in the study.
2. A medical illness, which in the view of the treating physician, has an anticipated life expectancy of less than 8 months.
3. Patients using any other dose administration aid (e.g. webster pack, automated devices)
4. Patients with physical disabilities precluding use of the DoseAid (e.g. tearing the sachets) and without a carer to assist them.
5. Patients with significant cognitive or psychiatric conditions precluding informed consent and use of DoseAid

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
The primary outcome will be difference between the intervention and usual care groups (intention to treat [ITT]) in prescription possession ratio at 8-months. Prescription Possession Ratio (PPR) is defined as the percentage of time that an individual has a valid prescription script according to practice prescription records in a given observation period. It will be assessing using the practice practice prescription records.[ End of study will occur after all patients in the intervention group finish 8 months follow-up in the intervention group. ]